gx-19
Biologicalexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 17, 2020 (NCT04445389)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05067946 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2021 | Genexine, Inc., Kalbe Farma TBK |
| NCT04915989 | Phase 1 | Feb 16, 2021 | Genexine, Inc., Yonsei University |
| NCT04715997 | Phase 1/Phase 2 (Phase 2) | Dec 30, 2020 | Genexine, Inc., Yonsei University |
| NCT04445389 | Phase 1/Phase 2 (Phase 2) | Jun 17, 2020 | Genexine, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genexine, Inc. | For profit | 4 | 4 | 3 | 2020 |
| Yonsei University | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Kalbe Farma TBK | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1